A Phase 2 interventional study of PF-06650833 and PF-06700841 in Acne Inversa, sponsored by Pfizer. Completed at 77 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 41st largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2019, is one of 61 in phase 2, and was the 49th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-06650833
Drug: PF-06650833
PF-6700841
Drug: PF-06700841
PF-06826647
Drug: PF-06826647
placebo
Drug: Placebo
400 mg QD
45 mg QD
400 mg QD
placebo
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)].
HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At week 16
Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI).
HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At weeks 1, 2, 4, 6, 8, and 12
Percentage of Participants Achieving a Total Abscess and Inflammatory Nodule (AN) Count of 0 or 1; 0, 1 or 2 at Week 16 - MR (FAS, NRI).
This estimand was intended to provide difference between treated and placebo in percentage of participants with a total AN count of 0 or 1, or 0, 1 or 2, respectively at week 16. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At week 16
Least Squares (LS) Mean of Percent Change From Baseline in AN Count at Weeks 1, 2, 4, 6, 8, 12 and 16 - Analysis of Covariance (ANCOVA) [FAS, Multiply Imputed (MI)].
The analysis of covariance (ANCOVA) model was implemented for statistical testing, which included terms of treatment group, the stratification factors, and the baseline value as the independent variable.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).
The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Percent Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).
The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Percentage of Participants Who Experienced a Hidradenitis Suppurativa (HS) Flare at Weeks 4, 8, 12 and 16 - MR [FAS, Only Observed Data (OBS)].
HS flare was defined as at least a 25% increase in AN count with a minimum increase of 2 relative to Baseline. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At weeks 4, 8, 12 and 16
Percentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)
The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Percentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)
The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Percentage of Participants Achieving Erythema Response Among Participants With Baseline Erythema Score ≥2 in at Least 1 Region at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS, NRI)
Erythema response was defined as achieving erythema score of 1 or 0 in all affected anatomic regions among participants who had an erythema score of 2 or more in at least 1 anatomic region at baseline. NRI for missing values which were related to withdrawal and all other events except for COVID-19. A four-point ordinal scale ranging was used: 0 (no redness), 1 (faint but discernible pink coloration), 2 (moderate red coloration), and 3 (very red or bright red coloration).
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Number of Participants With Treatment-Emergent Adverse Events (All Causalities)
The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.
Time frame: Up to 20 weeks
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related)
The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.
Time frame: Up to 20 weeks
Number of Participants With Incidence of Post-baseline Vital Signs of Clinical Concern - Increase From Baseline (Safety Analysis Set)
The vital signs were measured included temperature (Oral, Tympanic, Axillary or Temporal), pulse rate (beats/min) and blood pressure (mmHg).
Time frame: Up to 20 weeks
Number of Participants With Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) (Safety Analysis Set)
Laboratory test abnormalities included hematology, chemistry, urinalysis and biomarker.
Time frame: Up to 20 weeks
Number of Participants With Incidence of Post-baseline Electrocardiogram (ECG) Values of Clinical Concern (Safety Analysis Set)
ECG parameters included QT interval, QTc interval, PR interval, and QRS complex.
Time frame: Up to 20 weeks
Least Squares Mean of Absolute Score in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - Mixed Effect Model Repeated Measurement (MMRM) (FAS, OBS)
The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Change From Baseline in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - MMRM (FAS, OBS)
The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
Least Squares Mean of Absolute Score in Dermatology Life Quality Index (DLQI) Total Score up to Week 16 - MMRM (FAS, OBS)
The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes.
Time frame: At weeks 4, 8, 12 and 16
Least Squares Mean of Change From Baseline in DLQI Total Score up to Week 16 - MMRM (FAS, OBS)
The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined a change from baseline in total score, where negative value means improvement in DLQI.
Time frame: At weeks 4, 8, 12 and 16
Percentage of Participants Achieving DLQI Total Score of 0 or 1 up to Week 16 - MR (FAS With Baseline >1, NRI)
The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined the percentage of patients with complete resolution of dermatology specific quality of life impact, as assessed by a total score of ≤ 1 (range: 0 - 30), where higher percentage indicates better improvement in DLQI.
Time frame: At weeks 4, 8, 12 and 16
Plasma Concentration Versus Time Summary (Pharmacokinetic Concentration Set)
In summary statistics for pharmacokinetic, concentration values below the lower limit of quantification (LLOQ) was set to zero.
Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16
| Milestone | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Started | 48 | 47 | 52 | 47 |
| Completed | 35 | 30 | 37 | 31 |
| Not completed | 13 | 17 | 15 | 16 |
| Withdrew: Adverse event | 1 | 3 | 3 | 7 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 5 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 2 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 10 | 3 | 5 |
| Withdrew: Other | 0 | 0 | 1 | 2 |
HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)]. | 33.3 (22.2 to 45.5) | 34.0 (22.7 to 46.5) | 51.9 (39.7 to 64.0) | 37.0 (25.5 to 50.0) |
HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 | 16.7 (8.6 to 27.7) | 12.8 (5.7 to 22.7) | 15.4 (7.9 to 25.4) | 21.3 (12.0 to 32.2) |
| Week 2 | 25.0 (15.1 to 36.9) | 31.9 (20.8 to 44.4) | 32.0 (21.2 to 43.4) | 28.3 (17.6 to 40.4) |
| Week 4 | 31.9 (20.8 to 44.4) | 40.4 (28.3 to 53.5) | 39.2 (27.7 to 51.6) | 27.7 (17.2 to 40.3) |
| Week 6 | 37.5 (26.4 to 50.0) | 38.3 (27.1 to 51.3) | 44.2 (32.4 to 56.3) | 41.3 (29.0 to 54.5) |
| Week 8 | 43.8 (31.5 to 56.6) | 36.2 (25.1 to 48.7) | 44.2 (32.4 to 56.3) | 41.3 (29.0 to 54.5) |
| Week 12 | 41.7 (29.6 to 54.5) | 31.9 (20.8 to 44.4) | 50.0 (37.9 to 62.1) | 41.3 (29.0 to 54.5) |
This estimand was intended to provide difference between treated and placebo in percentage of participants with a total AN count of 0 or 1, or 0, 1 or 2, respectively at week 16. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Total AN Count of 0 or 1 | 16.7 (8.6 to 27.7) | 17.0 (8.8 to 28.3) | 28.8 (18.7 to 39.7) | 23.9 (15.1 to 35.0) |
| Total AN Count of 0, 1 or 2 | 22.9 (14.4 to 34.0) | 27.7 (17.2 to 40.3) | 38.5 (27.1 to 50.0) | 32.6 (21.3 to 45.5) |
The analysis of covariance (ANCOVA) model was implemented for statistical testing, which included terms of treatment group, the stratification factors, and the baseline value as the independent variable.
| Percent change | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 | -1.94 (-12.37 to 8.50) | -13.92 (-24.50 to -3.35) | -17.00 (-27.35 to -6.66) | -19.39 (-30.40 to -8.38) |
| Week 2 | -22.29 (-33.70 to -10.88) | -34.81 (-46.81 to -22.82) | -25.15 (-36.73 to -13.57) | -27.79 (-39.61 to -15.96) |
| Week 4 | -26.46 (-40.31 to -12.61) | -30.98 (-44.77 to -17.18) | -44.00 (-57.40 to -30.59) | -30.38 (-45.18 to -15.58) |
| Week 6 | -33.05 (-49.47 to -16.64) | -25.96 (-42.45 to -9.47) | -47.62 (-64.49 to -30.75) | -42.00 (-59.13 to -24.87) |
| Week 8 | -36.26 (-52.53 to -19.98) | -24.76 (-40.74 to -8.77) | -52.41 (-68.05 to -36.76) | -51.33 (-68.17 to -34.48) |
| Week 12 | -32.52 (-50.98 to -14.06) | -39.06 (-58.63 to -19.48) | -49.70 (-65.92 to -33.47) | -52.51 (-70.36 to -34.66) |
| Week 16 | -34.96 (-59.85 to -10.07) | -24.11 (-49.42 to 1.20) | -52.58 (-76.77 to -28.39) | -44.37 (-69.80 to -18.94) |
The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.
| Units on a scale | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 - Statistical Analysis (MI) - Absolute Score | 22.9 (19.6 to 26.1) | 21.4 (18.1 to 24.6) | 20.8 (17.7 to 24.0) | 21.4 (18.1 to 24.7) |
| Week 2 - Statistical Analysis (MI) - Absolute Score | 18.9 (15.8 to 22.1) | 18.0 (14.8 to 21.2) | 18.8 (15.7 to 21.9) | 19.0 (15.7 to 22.2) |
| Week 4 - Statistical Analysis (MI) - Absolute Score | 17.9 (14.8 to 20.9) | 17.5 (14.4 to 20.6) | 16.5 (13.6 to 19.5) | 13.3 (10.0 to 16.7) |
| Week 6 - Statistical Analysis (MI) - Absolute Score | 19.7 (16.0 to 23.3) | 18.1 (14.4 to 21.7) | 14.9 (11.4 to 18.5) | 14.2 (10.3 to 18.1) |
| Week 8 - Statistical Analysis (MI) - Absolute Score | 14.9 (11.5 to 18.3) | 15.9 (12.5 to 19.4) | 15.0 (11.7 to 18.4) | 11.1 (7.5 to 14.7) |
| Week 12 - Statistical Analysis (MI) - Absolute Score | 15.8 (12.6 to 18.9) | 14.5 (11.2 to 17.8) | 13.0 (10.0 to 16.0) | 12.9 (9.5 to 16.3) |
| Week 16 - Statistical Analysis (MI) - Absolute Score | 16.0 (12.4 to 19.6) | 13.4 (9.5 to 17.3) | 12.0 (8.8 to 15.3) | 13.4 (9.8 to 17.0) |
The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.
| Percent change | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 - Statistical Analysis (MI) - Percent Change from Baseline | -7.26 (-17.77 to 3.26) | -10.91 (-21.57 to -0.25) | -21.02 (-31.75 to -10.30) | -24.77 (-35.94 to -13.59) |
| Week 2 - Statistical Analysis (MI) - Percent Change from Baseline | -26.58 (-38.80 to -14.37) | -30.87 (-43.51 to -18.23) | -28.63 (-40.68 to -16.59) | -26.41 (-38.99 to -13.84) |
| Week 4 - Statistical Analysis (MI) - Percent Change from Baseline | -32.64 (-45.55 to -19.72) | -33.10 (-45.56 to -20.65) | -40.71 (-52.76 to -28.66) | -38.70 (-52.26 to -25.14) |
| Week 6 - Statistical Analysis (MI) - Percent Change from Baseline | -30.57 (-45.47 to -15.67) | -34.10 (-49.16 to -19.05) | -46.83 (-62.62 to -31.03) | -43.09 (-59.05 to -27.13) |
| Week 8 - Statistical Analysis (MI) - Percent Change from Baseline | -41.30 (-54.94 to -27.67) | -35.51 (-49.04 to -21.98) | -47.12 (-60.38 to -33.85) | -52.64 (-67.14 to -38.14) |
| Week 12 - Statistical Analysis (MI) - Percent Change from Baseline | -36.46 (-50.16 to -22.76) | -43.24 (-56.66 to -29.82) | -53.03 (-65.59 to -40.47) | -50.11 (-65.53 to -34.70) |
| Week 16 - Statistical Analysis (MI) - Percent Change from Baseline | -37.84 (-54.85 to -20.82) | -43.47 (-60.47 to -26.47) | -52.64 (-70.79 to -34.49) | -46.16 (-64.20 to -28.11) |
HS flare was defined as at least a 25% increase in AN count with a minimum increase of 2 relative to Baseline. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 4 | 13.3 (6.0 to 23.7) | 11.9 (5.9 to 22.7) | 4.8 (1.3 to 13.5) | 14.3 (7.1 to 26.0) |
| Week 8 | 9.3 (4.1 to 18.9) | 15.4 (6.9 to 27.7) | 2.3 (0.2 to 9.4) | 0 (0.0 to 7.3) |
| Week 12 | 17.5 (9.5 to 29.2) | 5.9 (1.6 to 16.9) | 2.4 (0.3 to 10.1) | 0 (0.0 to 8.2) |
| Week 16 | 17.1 (7.7 to 30.2) | 6.9 (1.8 to 20.0) | 0 (0.0 to 7.3) | 3.3 (0.4 to 14.0) |
The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 (Pain at its Worst) | 7.3 (2.7 to 17.3) | 18.9 (10.4 to 31.8) | 16.7 (9.1 to 27.7) | 19.5 (10.1 to 31.2) |
| Week 2 (Pain at its Worst) | 17.1 (9.3 to 28.4) | 21.6 (11.2 to 34.3) | 28.6 (17.4 to 41.0) | 24.4 (13.9 to 37.4) |
| Week 4 (Pain at its Worst) | 34.1 (23.0 to 46.9) | 16.2 (7.3 to 29.3) | 40.5 (27.7 to 54.3) | 31.7 (19.9 to 44.5) |
| Week 6 (Pain at its Worst) | 41.5 (28.4 to 55.5) | 21.6 (11.2 to 34.3) | 38.1 (25.6 to 52.0) | 29.3 (17.8 to 42.1) |
| Week 8 (Pain at its Worst) | 34.1 (23.0 to 46.9) | 29.7 (18.5 to 43.3) | 50.0 (36.5 to 63.5) | 27.5 (17.5 to 40.9) |
| Week 12 (Pain at its Worst) | 43.9 (31.2 to 57.9) | 29.7 (18.5 to 43.3) | 40.5 (27.7 to 54.3) | 35.0 (23.4 to 48.3) |
| Week 16 (Pain at its Worst) | 29.3 (17.8 to 42.1) | 21.6 (11.2 to 34.3) | 35.7 (23.7 to 48.0) | 35.0 (23.4 to 48.3) |
The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 (Average Pain) | 10.3 (4.5 to 21.0) | 17.6 (8.0 to 30.7) | 24.4 (13.9 to 37.4) | 8.6 (3.2 to 19.3) |
| Week 2 (Average Pain) | 17.9 (9.8 to 30.0) | 20.6 (11.3 to 34.9) | 36.6 (24.6 to 50.0) | 22.9 (11.9 to 36.5) |
| Week 4 (Average Pain) | 33.3 (21.0 to 47.1) | 20.6 (11.3 to 34.9) | 46.3 (33.9 to 60.2) | 34.3 (22.0 to 47.8) |
| Week 6 (Average Pain) | 48.7 (35.6 to 61.9) | 32.4 (19.7 to 46.2) | 48.8 (35.1 to 62.6) | 34.3 (22.0 to 47.8) |
| Week 8 (Average Pain) | 35.9 (23.9 to 50.0) | 26.5 (15.9 to 40.5) | 56.1 (42.1 to 68.8) | 29.4 (16.9 to 43.3) |
| Week 12 (Average Pain) | 41.0 (27.7 to 55.4) | 26.5 (15.9 to 40.5) | 41.5 (28.4 to 55.5) | 32.4 (19.7 to 46.2) |
| Week 16 (Average Pain) | 28.2 (17.8 to 42.1) | 20.6 (11.3 to 34.9) | 39.0 (26.2 to 53.1) | 32.4 (19.7 to 46.2) |
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percent change | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1-Pain at its Worst | -1.45 (-9.33 to 6.42) | -8.89 (-17.18 to -0.61) | -11.97 (-19.58 to -4.37) | -15.58 (-23.50 to -7.66) |
| Week 2-Pain at its Worst | -7.49 (-17.39 to 2.42) | -13.15 (-23.61 to -2.69) | -19.40 (-29.09 to -9.72) | -19.19 (-29.20 to -9.19) |
| Week 4-Pain at its Worst | -18.81 (-29.31 to -8.31) | -15.56 (-26.68 to -4.45) | -26.63 (-36.88 to -16.37) | -19.98 (-30.63 to -9.33) |
| Week 6-Pain at its Worst | -21.80 (-33.14 to -10.47) | -13.86 (-25.74 to -1.98) | -32.89 (-43.90 to -21.88) | -21.76 (-33.08 to -10.43) |
| Week 8-Pain at its Worst | -23.53 (-34.49 to -12.57) | -20.70 (-32.22 to -9.18) | -34.83 (-45.55 to -24.11) | -23.37 (-34.40 to -12.35) |
| Week 12-Pain at its Worst | -26.04 (-37.10 to -14.98) | -25.38 (-36.95 to -13.81) | -41.35 (-52.12 to -30.58) | -32.43 (-43.66 to -21.20) |
| Week 16-Pain at its Worst | -22.34 (-33.82 to -10.86) | -19.77 (-31.60 to -7.93) | -43.88 (-55.06 to -32.70) | -34.87 (-46.36 to -23.38) |
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percent change | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1-Average Pain | -2.47 (-9.45 to 4.51) | -8.64 (-16.06 to -1.22) | -13.53 (-20.29 to -6.77) | -8.81 (-16.53 to -1.10) |
| Week 2-Average Pain | -11.24 (-19.66 to -2.83) | -13.39 (-22.42 to -4.37) | -21.59 (-29.80 to -13.38) | -13.49 (-22.78 to -4.20) |
| Week 4-Average Pain | -24.04 (-34.14 to -13.94) | -16.00 (-26.79 to -5.21) | -33.01 (-42.90 to -23.13) | -18.67 (-29.57 to -7.77) |
| Week 6-Average Pain | -28.65 (-39.19 to -18.10) | -14.86 (-26.11 to -3.61) | -38.04 (-48.30 to -27.77) | -22.60 (-34.04 to -11.16) |
| Week 8-Average Pain | -30.75 (-41.20 to -20.31) | -21.78 (-32.86 to -10.70) | -39.59 (-49.80 to -29.39) | -22.11 (-33.48 to -10.75) |
| Week 12-Average Pain | -30.85 (-40.83 to -20.87) | -28.50 (-39.14 to -17.87) | -45.24 (-54.97 to -35.50) | -30.42 (-41.28 to -19.57) |
| Week 16-Average Pain | -27.83 (-37.98 to -17.69) | -23.80 (-34.41 to -13.18) | -46.21 (-56.05 to -36.37) | -31.92 (-42.93 to -20.91) |
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percent change | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1-Pain at its Worst | -0.23 (-0.59 to 0.13) | -0.54 (-0.91 to -0.16) | -0.68 (-1.03 to -0.33) | -0.71 (-1.09 to -0.33) |
| Week 2-Pain at its Worst | -0.52 (-0.98 to -0.05) | -0.84 (-1.32 to -0.36) | -1.07 (-1.52 to -0.62) | -0.91 (-1.40 to -0.43) |
| Week 4-Pain at its Worst | -1.22 (-1.74 to -0.70) | -1.15 (-1.68 to -0.61) | -1.67 (-2.17 to -1.16) | -1.19 (-1.74 to -0.65) |
| Week 6-Pain at its Worst | -1.55 (-2.10 to -1.01) | -1.06 (-1.62 to -0.50) | -1.97 (-2.50 to -1.45) | -1.43 (-2.00 to -0.87) |
| Week 8-Pain at its Worst | -1.56 (-2.11 to -1.01) | -1.40 (-1.97 to -0.83) | -1.95 (-2.48 to -1.41) | -1.43 (-2.01 to -0.86) |
| Week 12-Pain at its Worst | -1.80 (-2.35 to -1.26) | -1.74 (-2.30 to -1.18) | -2.37 (-2.89 to -1.84) | -1.80 (-2.37 to -1.23) |
| Week 16-Pain at its Worst | -1.44 (-2.00 to -0.89) | -1.35 (-1.91 to -0.80) | -2.51 (-3.04 to -1.98) | -2.01 (-2.58 to -1.44) |
Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.
| Percent change | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1-Average Pain | -0.19 (-0.53 to 0.15) | -0.44 (-0.79 to -0.09) | -0.62 (-0.96 to -0.29) | -0.50 (-0.86 to -0.14) |
| Week 2-Average Pain | -0.49 (-0.90 to -0.07) | -0.77 (-1.20 to -0.34) | -0.94 (-1.35 to -0.54) | -0.66 (-1.09 to -0.22) |
| Week 4-Average Pain | -1.22 (-1.72 to -0.73) | -1.10 (-1.61 to -0.60) | -1.73 (-2.21 to -1.25) | -1.02 (-1.53 to -0.51) |
| Week 6-Average Pain | -1.49 (-2.01 to -0.98) | -0.98 (-1.52 to -0.45) | -1.92 (-2.42 to -1.42) | -1.29 (-1.83 to -0.75) |
| Week 8-Average Pain | -1.56 (-2.09 to -1.02) | -1.35 (-1.89 to -0.80) | -1.88 (-2.39 to -1.37) | -1.30 (-1.85 to -0.74) |
| Week 12-Average Pain | -1.68 (-2.20 to -1.17) | -1.71 (-2.23 to -1.18) | -2.25 (-2.75 to -1.76) | -1.53 (-2.06 to -1.00) |
| Week 16-Average Pain | -1.40 (-1.93 to -0.87) | -1.37 (-1.89 to -0.84) | -2.29 (-2.79 to -1.79) | -1.77 (-2.31 to -1.23) |
Erythema response was defined as achieving erythema score of 1 or 0 in all affected anatomic regions among participants who had an erythema score of 2 or more in at least 1 anatomic region at baseline. NRI for missing values which were related to withdrawal and all other events except for COVID-19. A four-point ordinal scale ranging was used: 0 (no redness), 1 (faint but discernible pink coloration), 2 (moderate red coloration), and 3 (very red or bright red coloration).
| Percentage of participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1 | 6.5 (2.4 to 15.8) | 4.7 (1.2 to 13.2) | 8.7 (3.8 to 17.6) | 13.6 (6.1 to 24.3) |
| Week 2 | 10.9 (5.4 to 21.3) | 20.9 (12.3 to 33.3) | 17.8 (9.2 to 29.7) | 18.2 (9.4 to 30.0) |
| Week 4 | 13.3 (6.0 to 23.7) | 20.9 (12.3 to 33.3) | 28.3 (17.6 to 40.4) | 18.2 (9.4 to 30.0) |
| Week 6 | 13.0 (5.8 to 23.2) | 27.9 (17.0 to 39.9) | 23.9 (15.1 to 35.0) | 23.3 (13.2 to 35.5) |
| Week 8 | 15.2 (8.2 to 25.5) | 25.6 (16.3 to 37.7) | 28.3 (17.6 to 40.4) | 23.3 (13.2 to 35.5) |
| Week 12 | 15.2 (8.2 to 25.5) | 23.3 (13.2 to 35.5) | 30.4 (20.4 to 43.4) | 18.6 (9.6 to 30.2) |
| Week 16 | 13.0 (5.8 to 23.2) | 16.3 (8.8 to 27.0) | 28.3 (17.6 to 40.4) | 18.6 (9.6 to 30.2) |
The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.
| Participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Participants with adverse events | 23 | 26 | 30 | 29 |
| Participants with serious adverse events | 0 | 2 | 0 | 2 |
| Participants with severe adverse events | 1 | 2 | 1 | 4 |
| Participants discontinued from study due to adverse events | 0 | 1 | 1 | 6 |
| Participants discontinued study drug due to AE and continued Study | 1 | 2 | 2 | 1 |
| Participants with temporary discontinuation due to adverse events | 2 | 1 | 3 | 5 |
The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.
| Participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Participants with adverse events | 7 | 10 | 12 | 16 |
| Participants with serious adverse events | 0 | 1 | 0 | 1 |
| Participants with severe adverse events | 0 | 1 | 0 | 3 |
| Participants discontinued from study due to adverse events | 0 | 1 | 1 | 4 |
| Participants discontinued study drug due to AE and continued Study | 1 | 1 | 2 | 0 |
| Participants with temporary discontinuation due to adverse events | 1 | 1 | 0 | 2 |
The vital signs were measured included temperature (Oral, Tympanic, Axillary or Temporal), pulse rate (beats/min) and blood pressure (mmHg).
| Participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Supine Diastolic Blood Pressure (MMHG): Change >= 20mmHg increase | 2 | 1 | 2 | 4 |
| Supine Systolic Blood Pressure (MMHG): Change >= 30mmHg increase | 1 | 1 | 2 | 4 |
Laboratory test abnormalities included hematology, chemistry, urinalysis and biomarker.
| Participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Hematology: hemoglobin (g/dL) <0.8x lower limit of normal (LLN) | 1 | 0 | 4 | 0 |
| Hematology: Hematocrit (%) <0.8x LLN | 0 | 0 | 1 | 0 |
| Hematology: Erythrocytes (10^6/mm^3) <0.8x LLN | 0 | 0 | 3 | 1 |
| Hematology: Ery. Mean Corpuscular Volume (um^3) <0.9x LLN | 1 | 2 | 1 | 0 |
| Hematology: Ery. Mean Corpuscular Volume (um^3) >1.1x ULN | 0 | 2 | 1 | 1 |
| Hematology: Ery. Mean Corpuscular Hemoglobin (pg/cell) <0.9x LLN | 5 | 5 | 7 | 5 |
| Hematology: Ery. Mean Corpuscular Hemoglobin (pg/cell) >1.1x ULN | 0 | 0 | 0 | 0 |
| Hematology: Ery. Mean Corpuscular HGB Concentration (g/dL) <0.9x LLN | 6 | 3 | 6 | 6 |
| Hematology: Ery. Mean Corpuscular HGB Concentration (g/dL) >1.1x ULN | 0 | 0 | 0 | 0 |
| Hematology: Mean Platelet Volume (fL) <0.9x LLN | 0 | 0 | 0 | 2 |
| Hematology: Mean Platelet Volume (fL) >1.1x ULN | 1 | 0 | 0 | 0 |
| Hematology: Platelets (10^3/mm^3) <0.5x LLN | 0 | 0 | 0 | 1 |
| Hematology: Platelets (10^3/mm^3) >1.75x ULN | 0 | 0 | 1 | 3 |
| Hematology: Leukocytes (10^3/mm^3) <0.6x LLN | 0 | 0 | 1 | 3 |
| Hematology: Leukocytes (10^3/mm^3) >1.5x ULN | 4 | 1 | 1 | 0 |
| Hematology: Lymphocytes (10^3/mm^3) <0.8x LLN | 1 | 0 | 1 | 3 |
| Hematology: Lymphocytes (10^3/mm^3) >1.2x ULN | 5 | 2 | 7 | 4 |
| Hematology: Neutrophils (10^3/mm^3) <0.8x LLN | 0 | 0 | 3 | 8 |
| Hematology: Neutrophils (10^3/mm^3) >1.2x ULN | 8 | 3 | 6 | 4 |
| Hematology: Basophils (10^3/mm^3) >1.2x ULN | 0 | 0 | 0 | 0 |
| Hematology: Eosinophils (10^3/mm^3) >1.2x ULN | 0 | 1 | 0 | 0 |
| Hematology: Monocytes (10^3/mm^3) >1.2x ULN | 2 | 0 | 0 | 0 |
| Clinical Chemistry: Bilirubin (mg/dL) >1.5x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Aspartate Aminotransferase (U/L) >3.0x ULN | 0 | 1 | 1 | 0 |
| Clinical Chemistry: Alanine Aminotransferase (U/L) >3.0x ULN | 0 | 1 | 2 | 1 |
| Clinical Chemistry: Alkaline Phosphatase (U/L) >3.0x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Protein (g/dL) <0.8x LLN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Protein (g/dL) >1.2x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Albumin (g/dL) <0.8x LLN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Albumin (g/dL) >1.2x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Urea Nitrogen (mg/dL) >1.3x ULN | 0 | 1 | 0 | 2 |
| Clinical Chemistry: Creatinine (mg/dL) >1.3x ULN | 0 | 0 | 1 | 0 |
| Clinical Chemistry: Urate (mg/dL) >1.2x ULN | 3 | 3 | 4 | 6 |
| Clinical Chemistry: Cholesterol (mg/dL) >1.3x ULN | 2 | 1 | 4 | 2 |
| Clinical Chemistry: HDL Cholesterol (mg/dL) <0.8x LLN | 10 | 6 | 6 | 5 |
| Clinical Chemistry: LDL Cholesterol (mg/dL) >1.2x ULN | 1 | 1 | 3 | 2 |
| Clinical Chemistry: Triglycerides (mg/dL) >1.3x ULN | 5 | 4 | 6 | 7 |
| Clinical Chemistry: Sodium (mEq/L) <0.95x LLN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Sodium (mEq/L) >1.05x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Potassium (mEq/L) <0.9x LLN | 1 | 1 | 1 | 0 |
| Clinical Chemistry: Potassium (mEq/L) >1.1x ULN | 1 | 2 | 0 | 2 |
| Clinical Chemistry: Chloride (mEq/L) <0.9x LLN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Chloride (mEq/L) >1.1x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Calcium (mg/dL) <0.9x LLN | 0 | 2 | 0 | 0 |
| Clinical Chemistry: Calcium (mg/dL) >1.1x ULN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Bicarbonate (mEq/L) <0.9x LLN | 10 | 10 | 2 | 13 |
| Clinical Chemistry: Bicarbonate (mEq/L) >1.1x ULN | 0 | 1 | 0 | 0 |
| Clinical Chemistry: Glucose (mg/dL) <0.6x LLN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Glucose (mg/dL) >1.5x ULN | 1 | 2 | 1 | 3 |
| Clinical Chemistry: Creatine Kinase (U/L) >2.0x ULN | 6 | 2 | 18 | 20 |
| Clinical Chemistry: Glucose -FASTING (mg/dL) <0.6x LLN | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Glucose -FASTING (mg/dL) >1.5x ULN | 4 | 5 | 3 | 5 |
| Urinalysis: pH <4.5 | 0 | 0 | 0 | 0 |
| Urinalysis: pH >8 | 2 | 1 | 2 | 5 |
| Urinalysis: URINE Glucose (mg/dL) ≥1 | 4 | 6 | 2 | 4 |
| Urinalysis: Ketones (mg/dL) ≥1 | 9 | 6 | 8 | 12 |
| Urinalysis: URINE Protein (mg/dL) ≥1 | 32 | 30 | 29 | 32 |
| Urinalysis: URINE Hemoglobin ≥1 | 23 | 9 | 16 | 10 |
| Urinalysis: Urobilinogen (EU/dL) ≥1 | 3 | 4 | 7 | 5 |
| Urinalysis: URINE Bilirubin ≥1 | 0 | 0 | 0 | 0 |
| Urinalysis: Nitrite ≥1 | 3 | 4 | 6 | 3 |
| Urinalysis: Leukocyte Esterase ≥1 | 10 | 5 | 9 | 6 |
| Urinalysis: URINE Erythrocytes (/HPF) ≥20 | 4 | 2 | 5 | 1 |
| Urinalysis: Granular Casts (/LPF) >1 | 0 | 0 | 0 | 0 |
| Urinalysis: Hyaline Casts (/LPF) >1 | 1 | 1 | 1 | 2 |
| Urinalysis: RBC Casts (/LPF) >1 | 0 | 0 | 0 | 0 |
| Urinalysis: WBC Casts (/LPF) >1 | 0 | 0 | 0 | 0 |
| Urinalysis: Bacteria (/HPF) >20 | 6 | 6 | 5 | 4 |
| Biomarker: C Reactive Protein (mg/dL) >1.1x ULN | 37 | 29 | 37 | 30 |
ECG parameters included QT interval, QTc interval, PR interval, and QRS complex.
| Participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| PR INTERVAL, SINGLE BEAT (MSEC): Value>280 | 0 | 0 | 0 | 0 |
| QRS DURATION, SINGLE BEAT (MSEC): Value>120 | 2 | 0 | 3 | 1 |
| QT INTERVAL, SINGLE BEAT (MSEC): Value>500 | 0 | 0 | 0 | 0 |
| QTCB INTERVAL, SINGLE BEAT (MSEC): 450<Value<=480 | 12 | 12 | 16 | 7 |
| QTCB INTERVAL, SINGLE BEAT (MSEC): 480<Value<500 | 1 | 0 | 2 | 1 |
| QTCB INTERVAL, SINGLE BEAT (MSEC): Value>=500 | 1 | 0 | 1 | 0 |
| QTCB INTERVAL, SINGLE BEAT (MSEC): 30<=Chg<=60 | 9 | 12 | 13 | 6 |
| QTCB INTERVAL, SINGLE BEAT (MSEC): Chg>60 | 0 | 1 | 1 | 0 |
| QTCF INTERVAL, SINGLE BEAT (MSEC): 450<Value<=480 | 2 | 2 | 6 | 2 |
| QTCF INTERVAL, SINGLE BEAT (MSEC): 480<Value<500 | 1 | 0 | 1 | 0 |
| QTCF INTERVAL, SINGLE BEAT (MSEC): Value>=500 | 0 | 0 | 0 | 0 |
| QTCF INTERVAL, SINGLE BEAT (MSEC): 30<=Chg<=60 | 5 | 6 | 7 | 2 |
| QTCF INTERVAL, SINGLE BEAT (MSEC): Chg>60 | 0 | 1 | 1 | 0 |
The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.
| Units on a scale | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1-HSS0101-Pain At It's Worst | 5.67 (5.33 to 6.01) | 5.47 (5.13 to 5.82) | 5.19 (4.86 to 5.52) | 5.25 (4.90 to 5.60) |
| Week 2-HSS0101-Pain At It's Worst | 5.39 (4.95 to 5.84) | 5.10 (4.63 to 5.57) | 4.69 (4.25 to 5.12) | 4.83 (4.36 to 5.29) |
| Week 4-HSS0101-Pain At It's Worst | 4.75 (4.21 to 5.29) | 5.01 (4.42 to 5.59) | 4.36 (3.83 to 4.89) | 4.69 (4.11 to 5.26) |
| Week 6-HSS0101-Pain At It's Worst | 4.39 (3.80 to 4.98) | 5.02 (4.38 to 5.65) | 4.20 (3.61 to 4.79) | 4.60 (3.96 to 5.24) |
| Week 8-HSS0101-Pain At It's Worst | 4.46 (3.83 to 5.09) | 4.70 (4.02 to 5.37) | 4.14 (3.51 to 4.77) | 4.91 (4.22 to 5.60) |
| Week 12-HSS0101-Pain At It's Worst | 4.28 (3.63 to 4.92) | 4.44 (3.73 to 5.15) | 3.60 (2.95 to 4.24) | 4.35 (3.65 to 5.06) |
| Week 16-HSS0101-Pain At It's Worst | 4.77 (4.06 to 5.48) | 4.86 (4.09 to 5.62) | 3.53 (2.83 to 4.22) | 3.87 (3.11 to 4.62) |
| Week 1-HSS0102-Tenderness At It's Worst | 5.66 (5.33 to 5.99) | 5.66 (5.32 to 6.00) | 5.37 (5.05 to 5.69) | 5.35 (5.01 to 5.69) |
| Week 2-HSS0102-Tenderness At It's Worst | 5.46 (5.05 to 5.87) | 5.24 (4.81 to 5.67) | 5.06 (4.66 to 5.46) | 5.00 (4.57 to 5.43) |
| Week 4-HSS0102-Tenderness At It's Worst | 4.85 (4.33 to 5.38) | 5.07 (4.50 to 5.65) | 4.61 (4.09 to 5.13) | 4.75 (4.18 to 5.31) |
| Week 6-HSS0102-Tenderness At It's Worst | 4.65 (4.06 to 5.23) | 5.12 (4.49 to 5.75) | 4.41 (3.82 to 5.00) | 4.65 (4.02 to 5.29) |
| Week 8-HSS0102-Tenderness At It's Worst | 4.69 (4.08 to 5.31) | 4.78 (4.13 to 5.44) | 4.45 (3.84 to 5.06) | 5.04 (4.37 to 5.71) |
| Week 12-HSS0102-Tenderness At It's Worst | 4.40 (3.78 to 5.01) | 4.45 (3.77 to 5.13) | 3.90 (3.29 to 4.52) | 4.41 (3.74 to 5.09) |
| Week 16-HSS0102-Tenderness At It's Worst | 5.04 (4.36 to 5.73) | 5.08 (4.35 to 5.82) | 3.80 (3.14 to 4.47) | 3.93 (3.20 to 4.66) |
| Week 1-HSS0103-Swelling At It's Worst | 5.53 (5.20 to 5.86) | 5.43 (5.09 to 5.77) | 5.30 (4.98 to 5.62) | 5.07 (4.73 to 5.40) |
| Week 2-HSS0103-Swelling At It's Worst | 5.17 (4.76 to 5.58) | 4.93 (4.50 to 5.36) | 4.70 (4.31 to 5.10) | 4.77 (4.35 to 5.20) |
| Week 4-HSS0103-Swelling At It's Worst | 4.57 (4.07 to 5.07) | 4.73 (4.19 to 5.27) | 4.40 (3.91 to 4.89) | 4.66 (4.12 to 5.19) |
| Week 6-HSS0103-Swelling At It's Worst | 4.36 (3.79 to 4.94) | 5.06 (4.44 to 5.68) | 4.35 (3.77 to 4.92) | 4.60 (3.97 to 5.22) |
| Week 8-HSS0103-Swelling At It's Worst | 4.38 (3.81 to 4.96) | 4.67 (4.06 to 5.28) | 4.38 (3.81 to 4.96) | 4.88 (4.26 to 5.51) |
| Week 12-HSS0103-Swelling At It's Worst | 4.34 (3.75 to 4.93) | 4.40 (3.75 to 5.06) | 3.87 (3.28 to 4.47) | 4.30 (3.65 to 4.95) |
| Week 16-HSS0103-Swelling At It's Worst | 4.79 (4.12 to 5.45) | 5.02 (4.30 to 5.73) | 3.73 (3.08 to 4.37) | 3.77 (3.06 to 4.47) |
| Week 1-HSS0104-Tiredness At It's Worst | 5.55 (5.24 to 5.85) | 5.71 (5.40 to 6.02) | 4.98 (4.68 to 5.27) | 5.63 (5.32 to 5.94) |
| Week 2-HSS0104-Tiredness At It's Worst | 5.10 (4.69 to 5.51) | 5.16 (4.73 to 5.58) | 4.66 (4.26 to 5.06) | 5.36 (4.94 to 5.79) |
| Week 4-HSS0104-Tiredness At It's Worst | 5.05 (4.56 to 5.54) | 4.93 (4.41 to 5.46) | 4.24 (3.76 to 4.72) | 4.91 (4.39 to 5.42) |
| Week 6-HSS0104-Tiredness At It's Worst | 4.77 (4.23 to 5.32) | 4.81 (4.23 to 5.40) | 4.25 (3.71 to 4.80) | 4.89 (4.30 to 5.48) |
| Week 8-HSS0104-Tiredness At It's Worst | 4.86 (4.31 to 5.41) | 4.69 (4.11 to 5.28) | 4.32 (3.78 to 4.87) | 4.97 (4.38 to 5.56) |
| Week 12-HSS0104-Tiredness At It's Worst | 4.80 (4.21 to 5.38) | 4.46 (3.81 to 5.10) | 3.99 (3.40 to 4.57) | 4.95 (4.30 to 5.59) |
| Week 16-HSS0104-Tiredness At It's Worst | 4.59 (3.96 to 5.22) | 4.81 (4.14 to 5.49) | 4.03 (3.42 to 4.65) | 4.68 (4.01 to 5.36) |
| Week 1-HSS0105-Bothered By Appearance HS Lesion | 7.38 (7.08 to 7.69) | 7.43 (7.12 to 7.75) | 7.06 (6.76 to 7.36) | 7.37 (7.05 to 7.68) |
| Week 2-HSS0105-Bothered By Appearance HS Lesion | 7.34 (6.96 to 7.72) | 7.24 (6.84 to 7.64) | 6.55 (6.18 to 6.92) | 6.99 (6.59 to 7.38) |
| Week 4-HSS0105-Bothered By Appearance HS Lesion | 6.94 (6.48 to 7.41) | 7.26 (6.77 to 7.76) | 6.00 (5.54 to 6.46) | 6.65 (6.16 to 7.15) |
| Week 6-HSS0105-Bothered By Appearance HS Lesion | 6.69 (6.18 to 7.21) | 7.24 (6.69 to 7.79) | 6.00 (5.49 to 6.52) | 6.59 (6.04 to 7.15) |
| Week 8-HSS0105-Bothered By Appearance HS Lesion | 6.98 (6.42 to 7.53) | 6.82 (6.23 to 7.41) | 5.86 (5.31 to 6.42) | 6.67 (6.07 to 7.28) |
| Week 12-HSS0105-Bothered By Appearance HS Lesion | 6.46 (5.84 to 7.07) | 6.51 (5.84 to 7.17) | 5.59 (4.98 to 6.20) | 6.58 (5.91 to 7.24) |
| Week 16-HSS0105-Bothered By Appearance HS Lesion | 6.37 (5.69 to 7.05) | 6.77 (6.04 to 7.50) | 5.43 (4.76 to 6.09) | 6.37 (5.64 to 7.09) |
The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.
| Units on a scale | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 1-HSS0101-Pain At It's Worst | -0.19 (-0.53 to 0.15) | -0.39 (-0.74 to -0.04) | -0.67 (-1.00 to -0.34) | -0.61 (-0.96 to -0.26) |
| Week 2-HSS0101-Pain At It's Worst | -0.47 (-0.92 to -0.02) | -0.77 (-1.24 to -0.30) | -1.18 (-1.61 to -0.74) | -1.04 (-1.50 to -0.57) |
| Week 4-HSS0101-Pain At It's Worst | -1.12 (-1.66 to -0.58) | -0.86 (-1.44 to -0.27) | -1.51 (-2.04 to -0.98) | -1.18 (-1.76 to -0.60) |
| Week 6-HSS0101-Pain At It's Worst | -1.47 (-2.06 to -0.88) | -0.85 (-1.48 to -0.21) | -1.66 (-2.26 to -1.07) | -1.27 (-1.91 to -0.63) |
| Week 8-HSS0101-Pain At It's Worst | -1.40 (-2.03 to -0.77) | -1.17 (-1.84 to -0.49) | -1.72 (-2.35 to -1.09) | -0.96 (-1.65 to -0.27) |
| Week 12-HSS0101-Pain At It's Worst | -1.59 (-2.23 to -0.94) | -1.42 (-2.13 to -0.72) | -2.27 (-2.91 to -1.62) | -1.51 (-2.21 to -0.81) |
| Week 16-HSS0101-Pain At It's Worst | -1.09 (-1.80 to -0.38) | -1.01 (-1.77 to -0.24) | -2.34 (-3.03 to -1.64) | -2.00 (-2.75 to -1.24) |
| Week 1-HSS0102-Tenderness At It's Worst | -0.37 (-0.70 to -0.04) | -0.36 (-0.70 to -0.02) | -0.65 (-0.97 to -0.33) | -0.67 (-1.01 to -0.33) |
| Week 2-HSS0102-Tenderness At It's Worst | -0.56 (-0.97 to -0.15) | -0.78 (-1.21 to -0.35) | -0.96 (-1.36 to -0.56) | -1.02 (-1.45 to -0.59) |
| Week 4-HSS0102-Tenderness At It's Worst | -1.17 (-1.70 to -0.64) | -0.95 (-1.52 to -0.37) | -1.42 (-1.94 to -0.90) | -1.28 (-1.84 to -0.71) |
| Week 6-HSS0102-Tenderness At It's Worst | -1.38 (-1.96 to -0.79) | -0.90 (-1.53 to -0.27) | -1.61 (-2.20 to -1.02) | -1.37 (-2.00 to -0.73) |
| Week 8-HSS0102-Tenderness At It's Worst | -1.33 (-1.94 to -0.72) | -1.24 (-1.89 to -0.58) | -1.58 (-2.19 to -0.96) | -0.98 (-1.65 to -0.31) |
| Week 12-HSS0102-Tenderness At It's Worst | -1.63 (-2.24 to -1.01) | -1.57 (-2.25 to -0.90) | -2.12 (-2.74 to -1.50) | -1.61 (-2.28 to -0.93) |
| Week 16-HSS0102-Tenderness At It's Worst | -0.98 (-1.66 to -0.30) | -0.94 (-1.67 to -0.20) | -2.22 (-2.89 to -1.55) | -2.09 (-2.82 to -1.36) |
| Week 1-HSS0103-Swelling At It's Worst | -0.24 (-0.56 to 0.09) | -0.34 (-0.67 to 0.00) | -0.47 (-0.79 to -0.15) | -0.70 (-1.04 to -0.36) |
| Week 2-HSS0103-Swelling At It's Worst | -0.60 (-1.01 to -0.19) | -0.84 (-1.27 to -0.41) | -1.06 (-1.46 to -0.66) | -1.00 (-1.42 to -0.57) |
| Week 4-HSS0103-Swelling At It's Worst | -1.20 (-1.70 to -0.70) | -1.04 (-1.58 to -0.50) | -1.37 (-1.86 to -0.87) | -1.11 (-1.65 to -0.57) |
| Week 6-HSS0103-Swelling At It's Worst | -1.40 (-1.98 to -0.83) | -0.71 (-1.33 to -0.09) | -1.42 (-2.00 to -0.84) | -1.17 (-1.80 to -0.55) |
| Week 8-HSS0103-Swelling At It's Worst | -1.38 (-1.96 to -0.81) | -1.10 (-1.71 to -0.48) | -1.38 (-1.96 to -0.81) | -0.88 (-1.51 to -0.26) |
| Week 12-HSS0103-Swelling At It's Worst | -1.43 (-2.02 to -0.84) | -1.36 (-2.02 to -0.71) | -1.90 (-2.49 to -1.30) | -1.47 (-2.12 to -0.82) |
| Week 16-HSS0103-Swelling At It's Worst | -0.98 (-1.64 to -0.32) | -0.75 (-1.47 to -0.04) | -2.04 (-2.69 to -1.39) | -2.00 (-2.71 to -1.29) |
| Week 1-HSS0104-Tiredness At It's Worst | -0.04 (-0.34 to 0.26) | 0.12 (-0.19 to 0.43) | -0.61 (-0.91 to -0.32) | 0.04 (-0.26 to 0.35) |
| Week 2-HSS0104-Tiredness At It's Worst | -0.49 (-0.90 to -0.08) | -0.43 (-0.86 to -0.01) | -0.93 (-1.32 to -0.53) | -0.23 (-0.65 to 0.20) |
| Week 4-HSS0104-Tiredness At It's Worst | -0.54 (-1.03 to -0.05) | -0.66 (-1.18 to -0.13) | -1.35 (-1.83 to -0.87) | -0.68 (-1.20 to -0.16) |
| Week 6-HSS0104-Tiredness At It's Worst | -0.82 (-1.36 to -0.27) | -0.78 (-1.36 to -0.19) | -1.33 (-1.88 to -0.79) | -0.70 (-1.29 to -0.11) |
| Week 8-HSS0104-Tiredness At It's Worst | -0.73 (-1.28 to -0.18) | -0.90 (-1.48 to -0.31) | -1.26 (-1.81 to -0.72) | -0.62 (-1.21 to -0.02) |
| Week 12-HSS0104-Tiredness At It's Worst | -0.79 (-1.38 to -0.20) | -1.13 (-1.77 to -0.49) | -1.60 (-2.19 to -1.02) | -0.64 (-1.28 to 0.00) |
| Week 16-HSS0104-Tiredness At It's Worst | -1.00 (-1.63 to -0.37) | -0.78 (-1.45 to -0.10) | -1.56 (-2.17 to -0.94) | -0.90 (-1.58 to -0.23) |
| Week 1-HSS0105-Bothered By Appearance HS Lesion | -0.19 (-0.49 to 0.12) | -0.14 (-0.45 to 0.18) | -0.51 (-0.81 to -0.21) | -0.20 (-0.52 to 0.11) |
| Week 2-HSS0105-Bothered By Appearance HS Lesion | -0.23 (-0.61 to 0.15) | -0.33 (-0.73 to 0.07) | -1.02 (-1.39 to -0.65) | -0.58 (-0.98 to -0.19) |
| Week 4-HSS0105-Bothered By Appearance HS Lesion | -0.63 (-1.09 to -0.16) | -0.30 (-0.80 to 0.19) | -1.57 (-2.02 to -1.11) | -0.92 (-1.41 to -0.42) |
| Week 6-HSS0105-Bothered By Appearance HS Lesion | -0.88 (-1.39 to -0.36) | -0.33 (-0.88 to 0.22) | -1.56 (-2.08 to -1.05) | -0.97 (-1.53 to -0.42) |
| Week 8-HSS0105-Bothered By Appearance HS Lesion | -0.59 (-1.15 to -0.04) | -0.75 (-1.34 to -0.15) | -1.71 (-2.26 to -1.15) | -0.90 (-1.50 to -0.29) |
| Week 12-HSS0105-Bothered By Appearance HS Lesion | -1.11 (-1.73 to -0.50) | -1.06 (-1.73 to -0.40) | -1.98 (-2.59 to -1.37) | -0.99 (-1.66 to -0.33) |
| Week 16-HSS0105-Bothered By Appearance HS Lesion | -1.20 (-1.87 to -0.52) | -0.80 (-1.53 to -0.07) | -2.14 (-2.81 to -1.48) | -1.20 (-1.92 to -0.48) |
The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes.
| Units on a scale | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 4-Absolute Score | 10.2 (8.6 to 11.7) | 10.6 (9.0 to 12.2) | 9.6 (8.1 to 11.2) | 11.1 (9.4 to 12.8) |
| Week 8-Absolute Score | 10.8 (9.3 to 12.3) | 10.2 (8.7 to 11.8) | 9.6 (8.1 to 11.2) | 10.8 (9.2 to 12.4) |
| Week 12-Absolute Score | 10.7 (9.1 to 12.3) | 9.9 (8.1 to 11.7) | 8.7 (7.1 to 10.4) | 10.5 (8.7 to 12.2) |
| Week 16-Absolute Score | 9.5 (7.8 to 11.1) | 11.2 (9.4 to 13.1) | 8.2 (6.5 to 10.0) | 9.5 (7.7 to 11.4) |
The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined a change from baseline in total score, where negative value means improvement in DLQI.
| Units on a scale | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 4-Change from Baseline | -5.5 (-7.1 to -4.0) | -5.1 (-6.7 to -3.5) | -6.1 (-7.6 to -4.5) | -4.6 (-6.3 to -2.9) |
| Week 8-Change from Baseline | -4.9 (-6.4 to -3.4) | -5.5 (-7.0 to -3.9) | -6.1 (-7.6 to -4.5) | -4.9 (-6.5 to -3.3) |
| Week 12-Change from Baseline | -5.0 (-6.6 to -3.4) | -5.8 (-7.6 to -4.0) | -6.9 (-8.6 to -5.3) | -5.2 (-7.0 to -3.5) |
| Week 16-Change from Baseline | -6.2 (-7.9 to -4.5) | -4.5 (-6.3 to -2.6) | -7.5 (-9.2 to -5.7) | -6.2 (-8.0 to -4.3) |
The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined the percentage of patients with complete resolution of dermatology specific quality of life impact, as assessed by a total score of ≤ 1 (range: 0 - 30), where higher percentage indicates better improvement in DLQI.
| Percentage of Participants | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Week 4 | 6.8 (2.5 to 16.6) | 6.8 (2.5 to 16.6) | 8.9 (3.9 to 18.0) | 2.3 (0.2 to 9.4) |
| Week 8 | 2.2 (0.2 to 9.2) | 6.8 (2.5 to 16.6) | 8.7 (3.8 to 17.6) | 4.7 (1.2 to 13.2) |
| Week 12 | 4.4 (1.2 to 12.6) | 13.6 (6.1 to 24.3) | 10.9 (5.4 to 21.3) | 7.0 (2.6 to 17.0) |
| Week 16 | 4.4 (1.2 to 12.6) | 4.5 (1.2 to 12.9) | 10.9 (5.4 to 21.3) | 11.6 (5.8 to 22.9) |
In summary statistics for pharmacokinetic, concentration values below the lower limit of quantification (LLOQ) was set to zero.
| Nanograms per milliliter (ng/ml) | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|
| WEEK 1 0H | 31.79 ± 26.567 | 49.22 ± 64.871 | 281.7 ± 364.14 |
| WEEK 2 0H | 30.48 ± 35.796 | 51.48 ± 76.426 | 263.8 ± 388.42 |
| WEEK 4 0H | 25.33 ± 25.795 | 63.60 ± 77.180 | 215.6 ± 259.41 |
| WEEK 6 0H | 27.25 ± 29.905 | 47.38 ± 61.091 | 113.5 ± 140.62 |
| WEEK 8 0H | 34.72 ± 35.700 | 60.30 ± 92.758 | 277.2 ± 316.40 |
| WEEK 8 30MIN | 28.58 ± 24.510 | 254.7 ± 157.30 | 667.4 ± 560.37 |
| WEEK 8 1H | 45.70 ± 33.027 | 373.4 ± 174.51 | 817.2 ± 573.70 |
| WEEK 8 2H | 94.89 ± 48.222 | 296.0 ± 173.76 | 869.6 ± 549.58 |
| WEEK 8 4H | 112.4 ± 103.09 | 231.7 ± 168.11 | 784.8 ± 548.33 |
| WEEK 12 0H | 34.34 ± 32.046 | 52.95 ± 82.248 | 233.1 ± 322.19 |
| WEEK 16 0H | 39.41 ± 36.773 | 43.89 ± 67.413 | 244.4 ± 296.93 |
Collected over Up to 20 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/48 (0%) | 0/48 (0%) | 6/48 (12.5%) |
| PF-06650833 400mg QD | 0/47 (0%) | 2/47 (4.3%) | 10/47 (21.3%) |
| PF-06700841 45mg QD | 0/52 (0%) | 0/52 (0%) | 14/52 (26.9%) |
| PF-06826647 400mg QD | 0/47 (0%) | 2/47 (4.3%) | 18/47 (38.3%) |
| Event | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| COVID-19Infections and infestations | 0/48 | 0/47 | 0/52 | 1/47 |
| CellulitisInfections and infestations | 0/48 | 1/47 | 0/52 | 0/47 |
| Suicidal ideationPsychiatric disorders | 0/48 | 1/47 | 0/52 | 0/47 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/48 | 0/47 | 0/52 | 1/47 |
| Event | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD |
|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 0/48 | 0/47 | 4/52 | 6/47 |
| HidradenitisSkin and subcutaneous tissue disorders | 2/48 | 1/47 | 1/52 | 6/47 |
| HeadacheNervous system disorders | 3/48 | 5/47 | 4/52 | 3/47 |
| AcneSkin and subcutaneous tissue disorders | 1/48 | 4/47 | 5/52 | 4/47 |
| NauseaGastrointestinal disorders | 0/48 | 1/47 | 1/52 | 3/47 |
| Urinary tract infectionInfections and infestations | 1/48 | 3/47 | 2/52 | 0/47 |
All enrolled participants who received at least one dose of study treatment.
| Age, Continuous(Years) | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD | Total |
|---|---|---|---|---|---|
| Mean | 37.0 ± 8.95 | 39.9 ± 12.66 | 38.0 ± 11.76 | 36.6 ± 10.72 | 37.9 ± 11.10 |
| Sex: Female, Male(Participants) | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD | Total |
|---|---|---|---|---|---|
| Female | 42 | 34 | 40 | 35 | 151 |
| Male | 6 | 13 | 12 | 12 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 13 | 7 | 8 | 35 |
| Not Hispanic or Latino | 41 | 34 | 43 | 38 | 156 |
| Unknown or Not Reported | 0 | 0 | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | PF-06650833 400mg QD | PF-06700841 45mg QD | PF-06826647 400mg QD | Total |
|---|---|---|---|---|---|
| White | 32 | 26 | 26 | 28 | 112 |
| Black | 13 | 18 | 24 | 14 | 69 |
| Asian | 2 | 0 | 1 | 3 | 6 |
| American Indian or Alaska Native | 1 | 0 | 1 | 0 | 2 |
| Multiracial (Asian, White) | 0 | 0 | 0 | 1 | 1 |
| Not reported | 0 | 3 | 0 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2019 to primary completion in Jan 2022, 25 months.
Results were first posted in Jun 2023, 1 year 5 months after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 25 months is above that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zimlovisertib · PF-06700841 · Ropsacitinib